Literature DB >> 16569890

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.

Mary B Wire1, Katherine L Baker, Lori S Jones, Mark J Shelton, Yu Lou, Greg J Thomas, M Michelle Berrey.   

Abstract

To compare the effect of ritonavir on plasma amprenavir pharmacokinetics, healthy adults received either fosamprenavir (700 mg twice a day [BID]) or amprenavir (600 mg BID) alone and in combination with ritonavir (100 mg BID). Ritonavir increased plasma amprenavir pharmacokinetic parameters to a similar extent when coadministered with either fosamprenavir or amprenavir.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16569890      PMCID： PMC1426966          DOI： 10.1128/AAC.50.4.1578-1580.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.

Authors:  Mary Beth Wire; Charles Ballow; Sandra L Preston; Craig W Hendrix; Peter J Piliero; Yu Lou; Daniel S Stein
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

2.  A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

Authors:  Robin Wood; Joseph Eron; Keikawus Arasteh; Eugenio Teofilo; Christian Trepo; Jean-Michel Livrozet; Jane Yeo; Judith Millard; Mary Beth Wire; Odin J Naderer
Journal:  Clin Infect Dis       Date:  2004-07-26       Impact factor: 9.079

3.  SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

Authors:  Joseph C Gathe; Prudence Ive; Robin Wood; Dirk Schürmann; Nicholaos C Bellos; Edwin DeJesus; Andrzej Gladysz; Cindy Garris; Jane Yeo
Journal:  AIDS       Date:  2004-07-23       Impact factor: 4.177

4.  The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

Authors:  Amalia Rodriguez-French; Jack Boghossian; Glenda E Gray; Jeffrey P Nadler; Arnaldo R Quinones; Gladys E Sepulveda; Judith M Millard; Paul G Wannamaker
Journal:  J Acquir Immune Defic Syndr       Date:  2004-01-01       Impact factor: 3.731

5.  Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

Authors:  Robin Wood; Keikawus Arasteh; Hans-Jürgen Stellbrink; Eugenio Teofilo; François Raffi; Richard B Pollard; Joseph Eron; Jane Yeo; Judith Millard; Mary Beth Wire; Odin J Naderer
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

6.  Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.

Authors:  Eric S Furfine; Christopher T Baker; Michael R Hale; David J Reynolds; Jo A Salisbury; Andy D Searle; Scott D Studenberg; Dan Todd; Roger D Tung; Andrew Spaltenstein
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
  6 in total
  8 in total

1.  Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.

Authors:  Edwin DeJesus; Peter J Piliero; Kim Summers; Mary Beth Wire; Daniel S Stein; Amanda Masterman; Yu Lou; Sherene S Min; Mark J Shelton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.

Authors:  María J Pérez-Elías; María Larrousse Morellon; Enrique Ortega; José Hernández-Quero; Maribel Rodríguez-Torres; Bonaventura Clotet; Franco Felizarta; Felix Gutiérrez; Juan A Pineda; Garrett Nichols; Yu Lou; Mary Beth Wire
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

3.  Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.

Authors:  Isabelle Pellegrin; Dominique Breilh; Gaelle Coureau; Sébastien Boucher; Didier Neau; Patrick Merel; Denis Lacoste; Hervé Fleury; Marie-Claude Saux; Jean-Luc Pellegrin; Estibaliz Lazaro; François Dabis; Rodolphe Thiébaut
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

4.  Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.

Authors:  Olanrewaju Okusanya; Alan Forrest; Robin DiFrancesco; Sanela Bilic; Susan Rosenkranz; Michael F Para; Elizabeth Adams; Kevin E Yarasheski; Richard C Reichman; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

Review 5.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

Authors:  Mary Beth Wire; Mark J Shelton; Scott Studenberg
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Pharmacokinetic enhancers in HIV therapeutics.

Authors:  Kajal B Larson; Kun Wang; Cecile Delille; Igho Otofokun; Edward P Acosta
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

7.  Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.

Authors:  Manoli Vourvahis; Anna Plotka; Laure Mendes da Costa; Annie Fang; Jayvant Heera
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

8.  Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.

Authors:  Susan L Ford; Ya-Chi Chen; Yu Lou; Julie Borland; Sherene S Min; Geoffrey J Yuen; Mark J Shelton
Journal:  Antimicrob Agents Chemother       Date:  2007-12-03       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.